Bortezomib-induced histiocytoid Sweet syndrome
(2009) Journal of the American academy of dermatology — Vol. 60, n° 3, p. 496-497 (2009)
Files
pdfdocument.pdf
Restricted Access - Adobe PDF
- 173.37 KB
Details
- Authors
- Abstract
- Bortezomib, a proteasome inhibitor approved for the treatment of multiple myeloma, has been reported to be associated with Sweet syndrome. However, careful review of the histopathology of the first reported case and our case revealed similar histologic and immunohistochemical findings (a mononuclear dermal infiltrate) and not the usual neutrophilic infiltrate of Sweet syndrome. We suggest that the dermatitis induced by bortezomib is best classified as "histiocytoid Sweet syndrome." (J Am Acad Dermatol 2009;60:496-7.)
- Affiliations
Citations
Murase, J. E., Théate, I., Wu, J. J., Cole, G. W., Barr, R. J., & Dyson, S. W. (2009). Bortezomib-induced histiocytoid Sweet syndrome. Journal of the American academy of dermatology, 60(3), 496-497. https://doi.org/10.1016/j.jaad.2008.09.007 (Original work published 2009)